Business Standard

Friday, December 20, 2024 | 09:08 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Page 4 - Sun Pharma

Stocks to Watch: LIC, Delhivery, Sun Pharma, Vodafone Idea, IRCTC, SpiceJet

Stocks to Watch: Investors will react to LIC and Delhivery's Q4 numbers. The domestic GDP data for March quarter, slated to be released later today, will also be keenly monitored.

Stocks to Watch: LIC, Delhivery, Sun Pharma, Vodafone Idea, IRCTC, SpiceJet
Updated On : 31 May 2022 | 8:11 AM IST

Top headlines: Voda-Idea to raise funds, Sun Pharma Q4 loss, and more

From Sun Pharma posting loss in Q4 to Vodafone-Idea engaging in talks to raise funds, here are the top headlines on Tuesday morning

Top headlines: Voda-Idea to raise funds, Sun Pharma Q4 loss, and more
Updated On : 31 May 2022 | 7:30 AM IST

Sun Pharma posts Rs 2,277 cr Q4 loss over settlement of pending US lawsuits

Provides for the settlement charges, says adjusted profit for Q4FY22 at Rs 1582 cr, up 18% YoY after excluding exceptional items of Rs 3,935.7 cr and one-time tax gain of Rs 76.4 cr

Sun Pharma posts Rs 2,277 cr Q4 loss over settlement of pending US lawsuits
Updated On : 31 May 2022 | 1:29 AM IST

Sun Pharma eyes high single digit top line growth in FY23: Dilip Shanghvi

Drug major Sun Pharma on Monday said it expects high single-digit top-line growth in the current financial year with all its business verticals well placed to lead the charge. The company, which posted revenues of Rs 38,426 crore in FY22, aims to invest 7-8 per cent of sales in the R&D front in the ongoing fiscal. "We expect high single-digit top-line growth for FY23. All our businesses are positioned for growth. Ramp up in our global speciality business is expected to continue," Sun Pharma Managing Director Dilip Shanghvi said in an analyst call. He noted that markets across the globe were now in the process of normalising. "R&D investments are expected to be between 7-8 per cent of sales next year," Shanghvi noted. On its Halol-based manufacturing plant, he stated that the company will be filing its response to the FDA on the corrective actions to be undertaken to address the observations within the stipulated time. Earlier this month, the US health regulator had issued a ...

Sun Pharma eyes high single digit top line growth in FY23: Dilip Shanghvi
Updated On : 30 May 2022 | 9:08 PM IST

Top headlines: LIC Q4 PAT declines 18%; TaMo to acquire Ford's Sanand plant

Business Standard brings you the top headlines on Monday

Top headlines: LIC Q4 PAT declines 18%; TaMo to acquire Ford's Sanand plant
Updated On : 30 May 2022 | 6:10 PM IST

Sun Pharma posts net loss of Rs 2,277 cr in Q4, declares Rs 3 dividend

Sun Pharma's consolidated revenue rose 10% to Rs 9,446 cr in Q4FY22

Sun Pharma posts net loss of Rs 2,277 cr in Q4, declares Rs 3 dividend
Updated On : 30 May 2022 | 5:45 PM IST

Stocks to Watch: Hindalco, Muthoot Finance, Bharti Airtel, Sun Pharma, HDFC

Stocks to Watch today: JSW Steel, FSN E-Commerce Ventures (Nykaa), Jubilant Pharma, GAIL, Glenmark Pharma, Godrej Industries, PB Fintech (Policy Bazaar) will be in focus ahead of their Q4 results.

Stocks to Watch: Hindalco, Muthoot Finance, Bharti Airtel, Sun Pharma, HDFC
Updated On : 27 May 2022 | 8:07 AM IST

Sun Pharma to launch new oral lipid lowering drug under Brillo brand

Claims drug has a new mechanism of action compared to currently available lipid lowering agents, is indicated for people with inherited genetic disorder

Sun Pharma to launch new oral lipid lowering drug under Brillo brand
Updated On : 18 May 2022 | 4:15 PM IST

USFDA rush after 2-year lull: 20-30% new products may be open to inspection

The last two years saw limited physical inspections due to travel restrictions during the pandemic

USFDA rush after 2-year lull: 20-30% new products may be open to inspection
Updated On : 16 May 2022 | 6:02 AM IST

What is USFDA's Form 483?

The US carries out regular inspections at offshore drug making units to ensure quality compliance. In a recent check, the US FDA has issued Form 483 to Sun Pharma Halol unit. Let's demystify Form 483

What is USFDA's Form 483?
Updated On : 12 May 2022 | 7:00 AM IST

Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days

Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483
Updated On : 11 May 2022 | 1:22 AM IST

Top headlines: SBI to raise up to $2 bn in FY23; Asian Paints Q4 net slips

Business Standard brings you the top headlines on Tuesday

Top headlines: SBI to raise up to $2 bn in FY23; Asian Paints Q4 net slips
Updated On : 10 May 2022 | 6:41 PM IST

Sun Pharma slips over 2% after USFDA issues observations for Halol facility

In the past five days, the stock has fallen over 5 per cent. In comparison, the S&P BSE Sensex declined 3.75 per cent during the same period

Sun Pharma slips over 2% after USFDA issues observations for Halol facility
Updated On : 10 May 2022 | 1:23 PM IST

Aurobindo, Sun Pharma, Jubilant recall products in US market: USFDA

Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons

Aurobindo, Sun Pharma, Jubilant recall products in US market: USFDA
Updated On : 25 Apr 2022 | 12:51 AM IST

Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts
Updated On : 31 Mar 2022 | 1:44 AM IST

Sun Pharma, Ranbaxy Inc sign pact with 2 plaintiff groups to settle claims

Sun Pharma said has disputed the claims of the plaintiffs and defended these matters vigorously

Sun Pharma, Ranbaxy Inc sign pact with 2 plaintiff groups to settle claims
Updated On : 23 Mar 2022 | 10:52 PM IST

Sensex rebounds 1,059 pts from day's low, ends 697 pts up; RIL leaps 2.5%

CLOSING BELL: Tech M, Tata Motors, BPCL, ITC, JSW Steel, PowerGrid, Bajaj Auto, Infosys, TCS, Bajaj Finserv, Bharti Airtel, Wipro and IndusInd Bank were the other gainers

Sensex rebounds 1,059 pts from day's low, ends 697 pts up; RIL leaps 2.5%
Updated On : 22 Mar 2022 | 3:39 PM IST

Sun Pharma to acquire 11.28 pc stake in Zenotech from Daiichi Sankyo

Sun Pharma said it will pay Rs 5.32 crore for the stake

Sun Pharma to acquire 11.28 pc stake in Zenotech from Daiichi Sankyo
Updated On : 21 Mar 2022 | 10:54 PM IST

Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug

Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade.

Select pharma shares gain on tie-up for Pfizer Covid-19 oral treatment drug
Updated On : 21 Mar 2022 | 12:29 PM IST

Strong specialty sales and volumes keep it sunny for Sun Pharma

Rerating on the cards; the domestic business is expected to outperform

Strong specialty sales and volumes keep it sunny for Sun Pharma
Updated On : 20 Mar 2022 | 8:38 PM IST